Home > Insider Trading > Filing (0000950170-24-041237)

Filing Details

Issuer

Cik	Name	Symbol	Sector (SIC)	IRS No
1840574	Verve Therapeutics Inc.	VERV	Pharmaceutical Preparations (2834)	824800132

Insiders

Cik	Name	Reported Address	Insider Title	Director	Officer	Large Shareholder	Other
1964461	Joan Nickerson	C/O Verve Therapeutics, Inc. 201 Brookline Avenue, Suite 601 Boston MA 02215	Chief Administrative Officer	No	No	No	No

Reported Non-Derivative Transactions

Sec. Name	Acquisiton - Disposition	Date	Amount	Price	Remaning Holdings	Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
Common Stock	Acquisiton	2024-04-01	3,315	$0.00	10,173	No	4	M	Direct
Common Stock	Disposition	2024-04-02	1,514	$8.24	8,659	No	4	S	Direct

Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
No	4	M	Direct
No	4	S	Direct

Reported Derivative Transactions

Sec. Name	Sec. Type	Acquisiton - Disposition	Date	Amount	Price	Amount - 2	Price - 2
Common Stock	Restricted Stock Units	Disposition	2024-04-01	3,315	$0.00	3,315	$0.00

Remaning Holdings	Exercise Date	Expiration Date	Equity Swap Involved	Transaction Form Type	Transaction Code	Nature of Ownership
9,945			No	4	M	Direct

Footnotes

Restricted stock units ("RSUs") convert into common stock on a one-for-one basis. This transaction represents the settlement of RSUs in shares of common stock on their scheduled vesting date.
Includes 1,364 shares of the Company's common stock acquired in 2023 under the Verve Therapeutics, Inc. Amended and Restated 2021 Employee Stock Purchase Plan.
This transaction was effected pursuant to a durable automatic sale instruction plan adopted by the reporting person on March 17, 2023, and represents a broker-assisted sale of shares to satisfy the payment of withholding tax liability incurred upon the vesting of restricted stock units. The sale does not represent a discretionary trade by the reporting person.
On February 14, 2023, the reporting person was granted 13,260 RSUs pursuant to the Verve Therapeutics, Inc. 2021 Stock Incentive Plan. Each RSU represents a contingent right to receive one share of the Company's common stock upon vesting, with 25% of the RSU vesting on April 1, 2024 and the remainder vesting in equal annual installments until April 1, 2027.